drugset / Trial / NCT00000762

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762

Double-blindTreatment

Summary

To determine the safety and immunogenicity of gp160 (MicroGeneSys), rgp120/HIV-1MN (Genentech), and rgp120/HIV-1SF2 (BIOCINE) and their adjuvants in HIV-infected children 1 month to 18 years of age. The initiation of this immunotherapy trial will provide multiple benefits by assessing in asymptomatic HIV-infected children a therapy currently being tested in their adult counterparts, in the hope of forestalling the progression of HIV immunosuppression and clinical disease.

Timeline

Start
Primary completion
Completion
1996-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject gp160 Vaccine
Subject rgp120/HIV-1MN Unknown
Subject rgp120/HIV-1SF2 Unknown